GlassScriptPhysician profile
Karen E Hughes
NPI 1902864036
$3,036.47
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.00 · 2022: $165 · 2023: $1,998 · 2024: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003 · Education: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.21 |
| Education | $768.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $284.53 | 2022-2024 | Darzalex, Talvey, Imbruvica |
| Astellas Pharma US INC | $267.05 | 2023-2024 | Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $219.13 | 2021-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $166.08 | 2023 | Piqray, Kisqali |
| Gilead Sciences, INC. | $155.85 | 2023-2024 | Trodelvy |
| Genzyme Corporation | $129.46 | 2023 | |
| Seagen INC. | $121.49 | 2023 | Adcetris |
| Pfizer INC. | $116.67 | 2023-2024 | |
| Daiichi Sankyo INC. | $106.75 | 2023-2024 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $102.56 | 2022-2024 | Zejula |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Incyte Corporation | $97.52 | 2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $97.26 | 2023-2024 | Lynparza, Tagrisso |
| Eisai INC. | $91.69 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $89.01 | 2023-2024 | Opdivo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.